The Primary Results of the REDUCE-IT Trial

Purpose: to evaluate whether high-dose icosapent ethyl lowers ischemic event rates beyond statin therapy in at-risk patients

Trial Design: Phase 3b, randomized, double-blinded, placebo-controlled; median follow-up 4.5 years; >8000 patients on statin therapy treated with icosapent ethyl 4g/day or placebo; fasting triglycerides ≥150 mg/dL and <500 mg/dL; LDL-C >40 mg/dL and ≤100 mg/dL; prior CV event or other risk factors.

Primary Endpoints: composite CVD endpoint: CV death, MI, stroke, coronary revascularization, unstable angina.

Secondary Endpoint: composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke

Results: High-dose icosapent ethyl vs. placebo in at-risk patients significantly reduced the composite CVD endpoint: risk of CV death, non-fatal MI, stroke, coronary revascularization, and unstable angina needing hospitalization.

Presented by: Deepak L. Bhatt, AHA Scientific Sessions 2018 Chicago, Illinois © 2018, American Heart Association. All rights reserved